Survival of elderly patients with multiple myeloma

• Verfasst von: Merz, Maximilian [VerfasserIn]
• Verfasst von: Hillengaß, Jens [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Brenner, Hermann [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: Survival of elderly patients with multiple myeloma
• Titelzusatz: effect of upfront autologous stem cell transplantation
• Verf.angabe: Maximilian Merz, Lina Jansen, Felipe A. Castro, Jens Hillengass, Hans Salwender, Katja Weisel, Christof Scheid, Sabine Luttmann, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Alice Nennecke, Christian Straka, Christian Langer, Monika Engelhardt, Hermann Einsele, Nicolaus Kröger, Dietrich Beelen, Peter Dreger, Hermann Brenner, Hartmut Goldschmidt for the GEKID Cancer Survival Working Group and the DRST2
• E-Jahr: 2016
• Jahr: July 2016
• Umfang: 8 S.
• Teil: volume:62
• Teil: year:2016
• Teil: pages:1-8
• Teil: extent:8
• Fussnoten: Gesehen am 27.05.2016
• Titel Quelle: Enthalten in: European journal of cancer
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1965
• Jahr Quelle: 2016
• Band/Heft Quelle: 62(2016), Seite 1-8
• ISSN Quelle: 1879-0852
• DOI: doi:10.1016/j.ejca.2016.04.004
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Autologous stem cell transplantation
• Sach-SW: Elderly
• Sach-SW: Multiple myeloma
• Sach-SW: Population-based survival analysis
• K10plus-PPN: 1540038866

Abstract

Background: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma. Methods: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011. Conclusion: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.